Gallium-68 PSMA R2

Drug Profile

Gallium-68 PSMA R2

Alternative Names: 68Ga-PSMA-R2; Ga68-PSMA-R2

Latest Information Update: 22 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Johns Hopkins University
  • Developer Advanced Accelerator Applications
  • Class Antineoplastics; Imaging agents; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Prostate cancer

Most Recent Events

  • 23 May 2018 Phase-I/II clinical trials in Prostate cancer (Diagnosis, Hormone refractory, Metastatic disease) in USA (unspecified route)
  • 06 Apr 2018 Advanced Accelerator Applications plans the PROfind phase I/II trial for Prostate Cancer (Hormone-refractory,Metastatic disease, Diagnosis) in April 2018 , (NCT03490032)
  • 01 Feb 2018 Advanced Accelerator Applications has been acquired by Novartis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top